Monday, April 06, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Marketing Partnership Covering Costa Rica Brings First Success. In February, Nutriband signed an agreement with Costa Rica’s Innomedica CCB, making it the territory’s exclusive distributor of Nutriband products and AVERSA Fentanyl upon approval. Shortly afterward, the Costa Rican Ministry of Health approved the Nutriband kinesiology tapes for import and sale, making them the first Nutriband products that Innomedica has guided through local regulatory approvals. It plans to begin marketing efforts for the kinesiology tapes, the mosquito repellent patch, and begin AVERSA Fentanyl patch marketing in anticipation of approval.
Moving Forward With AVERSA Fentanyl. Nutriband is preparing to start its clinical trial testing to test the abuse deterrence of its proprietary AVERSA Fentanyl patch. This trial will test a generic fentanyl patch against the AVERSA Fentanyl patch to determine if substance abusers can obtain the drug without activating the with aversive chemicals. We expect the trial to begin around mid-FY2026.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.